Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT06027268
Title Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer (ToPCourT)
Acronym ToPCourT
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Wake Forest University Health Sciences
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.